ATE460170T1 - Therapeutische zusammensetzung enthaltend dentritische zellen und ihre verwendung - Google Patents

Therapeutische zusammensetzung enthaltend dentritische zellen und ihre verwendung

Info

Publication number
ATE460170T1
ATE460170T1 AT04739563T AT04739563T ATE460170T1 AT E460170 T1 ATE460170 T1 AT E460170T1 AT 04739563 T AT04739563 T AT 04739563T AT 04739563 T AT04739563 T AT 04739563T AT E460170 T1 ATE460170 T1 AT E460170T1
Authority
AT
Austria
Prior art keywords
composition containing
therapeutic composition
dendritic cells
relates
present
Prior art date
Application number
AT04739563T
Other languages
English (en)
Inventor
Peter Muehlradt
Armin Braun
Norbert Krug
Henning Weigt
Original Assignee
Helmholtz Infektionsforschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Infektionsforschung filed Critical Helmholtz Infektionsforschung
Application granted granted Critical
Publication of ATE460170T1 publication Critical patent/ATE460170T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464839—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04739563T 2003-06-04 2004-06-03 Therapeutische zusammensetzung enthaltend dentritische zellen und ihre verwendung ATE460170T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03012692A EP1484064A1 (de) 2003-06-04 2003-06-04 Therapeutische Zusammensetzung enthaltend dentritische Zellen und ihre Verwendung
PCT/EP2004/005996 WO2004108145A1 (en) 2003-06-04 2004-06-03 Therapeutical composition containing dentritic cells and use thereof

Publications (1)

Publication Number Publication Date
ATE460170T1 true ATE460170T1 (de) 2010-03-15

Family

ID=33155152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04739563T ATE460170T1 (de) 2003-06-04 2004-06-03 Therapeutische zusammensetzung enthaltend dentritische zellen und ihre verwendung

Country Status (6)

Country Link
US (2) US20070203185A1 (de)
EP (2) EP1484064A1 (de)
AT (1) ATE460170T1 (de)
CA (1) CA2524910A1 (de)
DE (1) DE602004025936D1 (de)
WO (1) WO2004108145A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19652586A1 (de) * 1996-12-17 1998-06-18 Biotechnolog Forschung Gmbh Dhc-Peptid und Mittel
WO2007122392A1 (en) * 2006-04-20 2007-11-01 King's College London Composition comprising a cytotoxic t-cell - inducing adjuvant
DE102009034779A1 (de) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
DE102011018499A1 (de) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
WO2015070031A1 (en) * 2013-11-08 2015-05-14 University Of Virginia Patent Foundation Compositions and methods for treating melanoma
CN107921063A (zh) 2015-07-02 2018-04-17 普莱瓦克斯免疫肿瘤学公司 用于采用登革病毒与树突细胞的联合疗法的组合物及方法
EP3865150A1 (de) 2015-09-26 2021-08-18 Primevax Immuno-Oncology, Inc. Kombinationstherapie mit dem dengue-virus und dendritischen zellen
CA3082779A1 (en) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
FR2796961B1 (fr) * 1999-07-29 2003-05-02 Chu Montpellier Procede d'obtention de cellules dentritiques, les cellules dentritiques ainsi obtenues et leurs utilisations a des fins cliniques
EP1291414A1 (de) * 2001-09-11 2003-03-12 Genethor GmbH Ex vivo Selektion von T-Zellen mit reduzierter Alloreaktivität (vermindertem Graft-versus-Host Effekt und erhöhtem Graft-verus-Leukemia Effekt) und Gebrauch derseleben bei Knochnemarktransplantationen
PL372098A1 (en) 2001-09-06 2005-07-11 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
EP1382352A1 (de) * 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung

Also Published As

Publication number Publication date
EP1484064A1 (de) 2004-12-08
DE602004025936D1 (de) 2010-04-22
EP1641474B1 (de) 2010-03-10
EP1641474A1 (de) 2006-04-05
WO2004108145A1 (en) 2004-12-16
CA2524910A1 (en) 2004-12-16
US20110070250A1 (en) 2011-03-24
US20070203185A1 (en) 2007-08-30
US8415152B2 (en) 2013-04-09

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2004019884A3 (en) Agents and methods for enhancing bone formation
PL374865A1 (en) Treatment of tnf alpha related disorders
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
EA200500497A3 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИ-IFN-γ НЕЙТРАЛИЗУЮЩИЕ АНТИТЕЛА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ ИНГИБИТОРОВ ПУТЕЙ IFN-γ
DK1624892T3 (da) Terapeutisk anvendelse af anti-CSI-antistoffer
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
CY1107682T1 (el) Παραγωγα 4-τετραζολυλ-4 φαινυλπιπεριδινης για θεραπεια πονου
CY1105982T1 (el) Συνδετες υποδοχεων γλυκοκορτικοειδων για την θepαπεια των μεταβολικων διαταραχων
HK1086011A1 (en) Ccr1 antagonists for the treatment of i.a demyelinating inflammatory disease
ATE539768T1 (de) Kombinationen von metabotropische-glutamat- rezeptor-antagonisten und ihre verwendung zur behandlung von suchtstörungen
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
WO2007031878A3 (en) Methods of treating nervous disorders
ATE460170T1 (de) Therapeutische zusammensetzung enthaltend dentritische zellen und ihre verwendung
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
WO2004026258A3 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease
BR9814867A (pt) Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
ATE314861T1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
BRPI0512709A (pt) métodos para prognóstico da resposta terapêutica a agentes atuando no receptor do hormÈnio do crescimento
BR0308753A (pt) Método para produzir pseudo-ilhotas
ES2176642T3 (es) Utilizacion de la sulbutiamina para la obtencion de composiciones farmaceuticas utiles en el tratamiento de ciertos t rastornos psicomotores y psicointelectuales.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties